CASE REPORT
Microscopic polyangiitis in a patient with
preexistent pulmonary fibrosis by 8 years
Case report and review of the literature
More details
Hide details
1
Resident doctor in pulmonology,
2nd Pulmonary Department, Sismanogleio
General Hospital of Attiki, Marousi, Greece
2
Pulmonologist, Junior Consultant,
2nd Pulmonary Department, Sismanogleio
General Hospital of Attiki, Marousi, Greece
3
Radiologist, Chief Physician, Department
of Computed Tomography and Magnetic
Resonance, Sismanogleio General Hospital
of Attiki, Marousi, Greece
4
Pathologist, Associate Professor,
1st Department of Pathology, Medical School,
National and Kapodistrian University of
Athens, Laiko General Hospital of Athens,
Athens, Greece
5
Pulmonologist, Chief Physician,
2nd Pulmonary Department, Sismanogleio
General Hospital of Attiki, Marousi, Greece
6
Pulmonologist, Head Physician, 2nd Pulmonary Department, Sismanogleio General Hospital of Attiki, Marousi, Greece
Publication date: 2021-06-17
Corresponding author
Vasiliki Filaditaki
Sismanogleio General Hospital of
Attiki, 1 Sismanogliou street, 15126, Marousi, Greece
Pneumon 2016;29(1):67-71
KEYWORDS
ABSTRACT
Microscopic polyangiitis (MPA) is a systemic necrotising vasculitis
that affects the small-caliber blood vessels and a common cause of
pulmonary-renal syndrome. We present a patient case with manifestations of rapidly progressive glomerulonephritis and alveolar
hemorrhage along with positive perinuclear antineutrophil cytoplasmic autoantibodies (p-ANCA) against myeloperoxidase (MPO). The
patient was diagnosed with pulmonary fibrosis (PF) based on the
findings of his chest computed tomography 8 years ago. 6 months
ago he demonstrated nephrotic syndrome, had a kidney biopsy with
findings of focal segmental necrotizing glomerulonephritis with
glomerular crescents and in the presence of positive MPO-ANCA
was diagnosed with MPA and treated with cyclophosphamide and
prednisolone with partial response. In his present hospitalization
he was admitted with symptoms of respiratory tract infection,
which was successfully treated with antibiotics. Upon its remission
he underwent a bronchoscopy with bronchoalveolar lavage, which
was compatible with alveolar hemorrhage (50% hemosiderin-laden
macrophages). The coexistence of MPA and PF is presenting more
often in recent studies, as a result of the most widespread use of
the high resolution chest computed tomography. The majority of
these patients have positive MPO-ANCA, clinically manifested PF
at the time of vasculitis diagnosis, radiological and pathological
pattern of usual interstitial pneumonia (UIP) and a worse prognosis
than those without PF. The pathogenetic association between these
two conditions is not clear and 3 hypothetic mechanisms have been
proposed: evolvement of fibrosis as a result of either the repeated
episodes of alveolar hemorrhage or the induced oxidative stress
in the presence of anti-MPO antibodies or reversely production of
ANCA as a result of the fibrotic inflammatory process.
REFERENCES (33)
1.
Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42:421-30.
2.
Chung SA, Seo P. Microscopic polyangiitis. Rheum Dis Clin North Am 2010; 36:545–58.
3.
Tzelepis GE, Kokosi M, Tzioufas A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010; 36:116-21.
4.
Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65:1-11.
5.
Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006; 2:661-70.
6.
Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 1990; 65:847-56.
7.
Hervier B, Pagnoux C, Agard C, et al. for the French Vasculitis Study Group. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009; 68:404-7.
8.
Arulkumaran N, Periselneris N, Gaskin G, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011;50:2035-43.
9.
Ahn JK, Hwang JW, Lee J, Jeon CH, Cha HS, Koh EM. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitides in Korea. Rheumatol Int 2012; 32:2979-86.
10.
Keogh K, Baqir M, Specks U, et al. Microscopic polyangiitis in the setting of usual interstitial pneumonia. Presse Med 2013; 42:703.
11.
Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014; 93:340-9.
12.
Huang H, Wang YX, Jiang CG et al. A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China. BMC Pulm Med 2014; 14:8.
13.
Sada KE, Yamamura M, Harigai M, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ter 2014; 16:R101.
14.
Furuta S, Chaudhry AN, Hamano Y, et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol 2014; 41:325-33.
15.
Fernandez Casares M, Gonzalez A, Fielli M, Caputo F, Bottinelli Y, Zamboni M. Microscopic polyangiitis associated with pulmonary fibrosis. Clin Rheumatol 2015; 34:1273-7.
16.
Hirayama K, Kobayashi M, Usui J, et al. on behalf of the Japanese RPGN Study Group of Progressive Renal Disease. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibodyassociated renal vasculitis in Japan. Nephrol Dial Transplant 2015; 30 Suppl 1:i83-93.
17.
Schirmer JH, Wright MN, Vonthein R, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford) 2015; pii:kev286.
18.
Katsumata Y, Kawaguchi Y, Yamanaka H. Interstitial Lung Disease with ANCA-associated Vasculitis. Clin Med Insights Circ Respir Pulm Med 2015; 9(Suppl 1):51-6.
19.
Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology 2004; 9:190-6.
20.
Foulon G, Delaval P, Valeyre D, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008; 102: 1392-8.
21.
Nozu T, Kondo M, Suzuki K, Tamaoki J, Nagai A. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration 2009; 77:407-15.
22.
Tanaka T, Otani K, Egashira R, et al. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. Respir Med 2012; 106:1765-70.
23.
Ando M, Miyazaki E, Ishii T, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med 2013; 107:608-15.
24.
Kagiyama N, Takayanagi N, Kanauchi T, et al. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Resp Res 2015; 2:e000058.
25.
Ozaki S, Atsumi T, Hayashi T, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol 2012; 22:394-404.
26.
Homma S, Suzuki A, Sato K. Pulmonary involvement in ANCAassociated vasculitis from the view of the pulmonologist. Clin Exp Nephrol 2013; 17:667-71.
27.
Flores-Suárez LF. Limited pulmonary MPA, a new MPA entity? A rheumatologist’s perspective. Clin Exp Nephrol 2013; 17:672-5.
28.
Gaudin PB, Askin FB, Falk RJ, Jennette JC. The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol 1995; 104:7-16.
29.
Yamada H. ANCA-associated lung fibrosis. Semin Respir Crit Care Med 2011; 32:322-7.
30.
Schnabel A, Reuter M, Csernok E, Richter C, Gross WL. Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Eur Respir J 1999; 14:118-24.
31.
Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a “pulmonary-muscle” syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis? Arthritis Rheum 2007; 56:2065-71.
32.
Guilpain P, Chereau C, Goulvestre C, et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J 2011; 37:1503-13.
33.
Ando Y, Okada F, Matsumoto S, Mori H. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPOANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr 2004; 28:710-6.